Ben Derman, MD, specializes in hematology and oncology. Dr. Derman is an expert in multiple myeloma and other plasma cell disorders, such as monoclonal gammopathy, amyloidosis, plasmacytoma, and POEMS syndrome. He also diagnoses and treats cancerous conditions and uses the most innovative techniques, including CAR T-cell therapy and stem cell transplantation to deliver long-term success for his patients.
Along with his clinical practice, Dr. Derman remains committed to research. Currently, he is focused on identifying strategies that can lead to a possible cure for multiple myeloma, including using very sensitive tests that measure small amounts of residual cancer cells in the body called ‘minimal residual disease’ (MRD) to guide decision making.
Dr. Derman is also investigating new methods and therapies designed to improve outcomes and quality of life for his patients. Additionally, he is interested in evaluating reasons for racial disparities in multiple myeloma outcomes to better understand and care for those patients. His work has been published in several peer-reviewed journals, including the Journal of Immunotherapy of Cancer, Blood, Blood Advances, Blood Cancer Journal, Leukemia and Lymphoma and British Journal of Haematology.
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity.
Intrathecal chemotherapy for ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood Adv. 2025 May 07.
PMID: 40334078
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025.
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025. J Natl Compr Canc Netw. 2025 05; 23(5):132-140.
PMID: 40340857
Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias.
Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias. Front Immunol. 2025; 16:1558275.
PMID: 40264764
Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review.
Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review. Cancers (Basel). 2025 Apr 05; 17(7).
PMID: 40227780
Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma.
Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma. Blood Cancer J. 2025 Mar 28; 15(1):47.
PMID: 40155599
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System.
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System. J Appl Lab Med. 2025 Mar 03; 10(2):235-249.
PMID: 39699179
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma.
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma. Leukemia. 2025 Apr; 39(4):816-826.
PMID: 39910285
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025 Mar; 39(3):543-554.
PMID: 39870767
Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma.
Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma. Blood Neoplasia. 2025 Feb; 2(1):100065.
PMID: 40454405
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System.
Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System. J Appl Lab Med. 2024 Dec 19.
PMID: 39699179